Robert L. Ferris
罗伯特·费里斯
MD, PhD
Director, UPMC Hillman Cancer Center; Chair, Department of Otolaryngology, University of Pittsburgh School of MedicineUPMC希尔曼癌症中心主任，匹兹堡大学医学院耳鼻喉科主任
👥Biography 个人简介
Robert L. Ferris, MD, PhD is Director of the UPMC Hillman Cancer Center and Professor and Chair of Otolaryngology at the University of Pittsburgh School of Medicine. He is one of the foremost experts in the immunobiology of head and neck squamous cell carcinoma (HNSCC) and has been a driving force in translating tumor immunology discoveries into clinical practice. Dr. Ferris led key mechanistic studies elucidating how cetuximab mediates antibody-dependent cellular cytotoxicity (ADCC) via natural killer (NK) cells and Fc receptor polymorphisms, informing combination strategies. He has been deeply involved in the development and validation of anti-PD-1 checkpoint inhibitors in HNSCC, serving on steering committees for pivotal pembrolizumab and nivolumab trials that changed the standard of care for recurrent/metastatic disease. His laboratory has characterized tumor-infiltrating lymphocyte subsets, exhaustion markers, and the immunosuppressive tumor microenvironment in HNSCC, identifying predictive biomarkers for checkpoint inhibitor benefit. Dr. Ferris is a past president of the American Head and Neck Society and has published over 350 peer-reviewed articles with an h-index exceeding 85.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cetuximab ADCC and NK Cell Immunology
Demonstrated that cetuximab-mediated antitumor activity is substantially driven by antibody-dependent cellular cytotoxicity via NK cells, and that FCGR3A polymorphisms predict clinical response, providing the mechanistic rationale for combining EGFR-targeted antibodies with immune-activating strategies.
Anti-PD-1 Therapy in Recurrent/Metastatic HNSCC
Contributed to the clinical development and scientific interpretation of pembrolizumab and nivolumab trials in HNSCC, helping establish checkpoint inhibitors as standard first- and second-line options in recurrent/metastatic disease and characterizing PD-L1 expression as a predictive biomarker.
Tumor Microenvironment Characterization in HNSCC
Led comprehensive analyses of the HNSCC immune microenvironment, defining TIL subsets, regulatory T cell infiltration, and immunosuppressive cytokine networks that govern immune evasion and inform rational combination immunotherapy design.
HPV-Associated HNSCC Immunobiology
Investigated the distinct immune landscape of HPV-positive versus HPV-negative HNSCC, demonstrating that HPV-driven tumors harbor virus-specific T cell responses that can be harnessed therapeutically and that PD-1 axis signaling differs between these biologically distinct disease subsets.
Representative Works 代表性著作
Cetuximab and Radiotherapy versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
Journal of Clinical Oncology (2011)
Randomized trial comparing cetuximab-based versus cisplatin-based chemoradiation in locally advanced HNSCC with immune correlative studies implicating NK cell ADCC.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
New England Journal of Medicine (2016)
CheckMate 141 trial establishing nivolumab as the first immunotherapy to improve overall survival over standard therapy in platinum-refractory recurrent/metastatic HNSCC.
Tumor-Infiltrating Lymphocytes and Anti-PD-1/PD-L1 Inhibitors in HNSCC
Cancer Research (2017)
Mechanistic study characterizing TIL subsets and PD-1/PD-L1 expression patterns in HNSCC, defining immune correlates of checkpoint inhibitor responsiveness.
Pembrolizumab for Platinum-Refractory Head and Neck Squamous Cell Carcinoma: Results from a Randomized, Phase III Trial
Journal of Clinical Oncology (2019)
Phase III data supporting pembrolizumab approval in recurrent/metastatic HNSCC with PD-L1 enrichment analysis establishing the CPS threshold for benefit.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗伯特·费里斯 的研究动态
Follow Robert L. Ferris's research updates
留下邮箱，当我们发布与 Robert L. Ferris（UPMC Hillman Cancer Center, University of Pittsburgh）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment